Nuvalent (NASDAQ:NUVL) Lowered to Hold Rating by Wells Fargo & Company

Nuvalent (NASDAQ:NUVL) was downgraded by equities research analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

NUVL has been the subject of a number of other research reports. HC Wainwright downgraded shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 target price for the company. in a research note on Tuesday. Raymond James Financial downgraded shares of Nuvalent from an “outperform” rating to a “market perform” rating in a research note on Tuesday. TD Cowen downgraded shares of Nuvalent from a “buy” rating to a “hold” rating in a research note on Tuesday. Sanford C. Bernstein began coverage on shares of Nuvalent in a research note on Thursday, May 21st. They set an “outperform” rating and a $189.00 target price for the company. Finally, Wedbush downgraded shares of Nuvalent from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $125.00 to $124.00 in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $133.27.

Nuvalent Trading Up 39.3%

Nuvalent stock opened at $123.25 on Tuesday. Nuvalent has a twelve month low of $71.13 and a twelve month high of $123.62. The stock’s fifty day simple moving average is $102.91 and its 200-day simple moving average is $103.08. The firm has a market capitalization of $9.74 billion, a P/E ratio of -20.34 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period last year, the firm earned ($1.18) earnings per share. Sell-side analysts predict that Nuvalent will post -5.74 earnings per share for the current year.

Insider Activity at Nuvalent

In other Nuvalent news, CFO Alexandra Balcom sold 11,430 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $105.21, for a total value of $1,202,550.30. Following the completion of the transaction, the chief financial officer directly owned 85,533 shares of the company’s stock, valued at approximately $8,998,926.93. This trade represents a 11.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James Richard Porter sold 30,000 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $101.69, for a total transaction of $3,050,700.00. Following the completion of the sale, the chief executive officer owned 324,879 shares in the company, valued at $33,036,945.51. This represents a 8.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 96,953 shares of company stock valued at $9,956,364. 5.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Nuvalent

Several large investors have recently modified their holdings of NUVL. GAMMA Investing LLC grew its position in shares of Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after purchasing an additional 108 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after acquiring an additional 195 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Nuvalent during the third quarter worth approximately $38,000. NBC Securities Inc. acquired a new stake in Nuvalent during the fourth quarter worth approximately $125,000. Finally, KBC Group NV boosted its position in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after acquiring an additional 297 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK announced a definitive all-cash acquisition of Nuvalent for about $10.6 billion, giving shareholders $124 per share and sparking a takeover-driven rerating. Reuters article
• Positive Sentiment: The deal adds Nuvalent’s late-stage lung cancer pipeline to GSK’s oncology business, which likely helped justify the premium and support investor enthusiasm. WSJ article
• Positive Sentiment: Options activity surged sharply, suggesting traders were positioning for further upside and volatility around the buyout news. Quiver Quant article
• Neutral Sentiment: Several analysts adjusted ratings and price targets to around the deal value, which reflects the market now focusing more on the acquisition price than standalone fundamentals. Benzinga article
• Negative Sentiment: Law firms and investor groups launched investigations into whether shareholders are receiving a fair price, adding a layer of deal-related uncertainty. GlobeNewswire article
• Negative Sentiment: Recent analyst downgrades to neutral could temper expectations for any upside beyond the takeover price. Benzinga article

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.